The 2025 ESC/EAS Dyslipidaemia Focused Update: Clinical Interpretation and Practical Implications - PubMed
3 days ago
- #Dyslipidaemia Management
- #ESC/EAS Guidelines
- #LDL Cholesterol Targets
- The 2025 ESC/EAS Dyslipidaemia Focused Update revises the 2019 guidelines with new evidence influencing clinical decisions.
- LDL-C treatment targets remain unchanged, but the approach to achieving them is reshaped, emphasizing faster intensification and broader combination therapy.
- Improved risk stratification tools include SCORE2/SCORE2-OP, lipoprotein(a) [Lp(a)], and coronary artery calcium (CAC) scoring.
- New therapies like bempedoic acid, inclisiran, and evinacumab are supported, especially for high-risk patients or those with statin intolerance.
- A proactive, early-intensification approach is reinforced for acute coronary syndrome (ACS) patients.
- The update promotes earlier, more personalized, and sustained lipid lowering to reduce cumulative atherosclerotic exposure.